Emily Curran

Emily K. Curran

Assistant Professor

Vontz Center

COM IM Hematology/Oncology Division - 0562

Professional Summary

Current Role
Emily K. Curran, MD, is an Assistant Professor in the Department of Medicine, Section of Hematology & Oncology at the UC College of Medicine. 


Current Clinical Focus and Interests
Dr. Curran’s clinical interest focuses on the care of patients with hematologic malignancies and, in particular, acute leukemia. Her particular area of expertise is in treatment of adolescent and young adult (AYA) patients with hematologic malignancies. She is a member of the American Society of Hematology (ASH) and the American Society of Clinical Oncology (ASCO).


Summary of Background/Previous Work History, Education and AchievementsDr. Curran is a graduate of Stanford University and Stanford University School of Medicine. She completed her residency training in Internal Medicine and fellowship in Hematology & Oncology at the University of Chicago. She completed an additional fellowship in Clinical Pharmacology and Pharmacogenomics at the University of Chicago.
 

Education

BA, Stanford University Stanford, CA, 2002 (Human Biology)

MD, Stanford University School of Medicine Stanford, CA, 2008

Residency, University of Chicago Medical Center Chicago, IL, 2009 (Internal Medicine)

Fellowship, University of Chicago Medical Center Chicago, IL, 2015 (Division of Hematology/Oncology)

Fellowship, University of Chicago Chicago, IL, 2016 (Clinical Pharmacology and Pharmacogenomics)

Clinical Focus

Hematology and Oncology

Specialities

Hematology

Internal Medicine

Medical Oncology

Certifications

American Board of Internal Medicine (Hematology)

10/31/2017

American Board of Internal Medicine

08/15/2011

American Board of Internal Medicine (Medical Oncology)

10/27/2016

Publications

Peer Reviewed Publications

Curran, Emily; Stock, Wendy (2019. ) Taking a "BiTE out of ALL": blinatumomab approval for MRD-positive ALL.Blood, , 133 (16 ) ,1715-1719

Wang, Amy Y; Weiner, Howard; Green, Margaret; Chang, Hua; Fulton, Noreen; Larson, Richard A; Odenike, Olatoyosi; Artz, Andrew S; Bishop, Michael R; Godley, Lucy A; Thirman, Michael J; Kosuri, Satyajit; Churpek, Jane E; Curran, Emily; Pettit, Kristen; Stock, Wendy; Liu, Hongtao (2018. ) A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia.Journal of hematology & oncology, , 11 (1 ) ,4

Curran, Emily K; Godfrey, James; Kline, Justin (2017. ) Mechanisms of Immune Tolerance in Leukemia and Lymphoma.Trends in immunology, , 38 (7 ) ,513-525

Yap, Kai Lee; Furtado, Larissa V; Kiyotani, Kazuma; Curran, Emily; Stock, Wendy; McNeer, Jennifer L; Kadri, Sabah; Segal, Jeremy P; Nakamura, Yusuke; Le Beau, Michelle M; Gurbuxani, Sandeep; Raca, Gordana (2017. ) Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL).Leukemia & lymphoma, , 58 (4 ) ,950-958

Curran, Emily; Chen, Xiufen; Corrales, Leticia; Kline, Douglas E; Dubensky, Thomas W; Duttagupta, Priyanka; Kortylewski, Marcin; Kline, Justin (2016. ) STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia.Cell reports, , 15 (11 ) ,2357-66

Curran, Emily; Stock, Wendy (2015. ) How I treat acute lymphoblastic leukemia in older adolescents and young adults.Blood, , 125 (24 ) ,3702-10

Curran, Emily; Corrales, Leticia; Kline, Justin (2015. ) Targeting the innate immune system as immunotherapy for acute myeloid leukemia.Frontiers in oncology, , 5 ,83

Curran, Emily; Smith, Sonali M (2014. ) Phosphoinositide 3-kinase inhibitors in lymphoma.Current opinion in oncology, , 26 (5 ) ,469-75

Jain, Nitin; Curran, Emily; Iyengar, Neil M; Diaz-Flores, Ernesto; Kunnavakkam, Rangesh; Popplewell, Leslie; Kirschbaum, Mark H; Karrison, Theodore; Erba, Harry P; Green, Margaret; Poire, Xavier; Koval, Greg; Shannon, Kevin; Reddy, Poluru L; Joseph, Loren; Atallah, Ehab L; Dy, Philip; Thomas, Sachdev P; Smith, Scott E; Doyle, L Austin; Stadler, Walter M; Larson, Richard A; Stock, Wendy; Odenike, Olatoyosi (2014. ) Phase II study of the oral MEK inhibitor selumetinib in advanced acute myelogenous leukemia: a University of Chicago phase II consortium trial.Clinical cancer research : an official journal of the American Association for Cancer Research, , 20 (2 ) ,490-8

Partap, Sonia; Curran, Emily K; Propp, Jennifer M; Le, Gem M; Sainani, Kristin L; Fisher, Paul Graham (2009. ) Medulloblastoma incidence has not changed over time: a CBTRUS study.Journal of pediatric hematology/oncology, , 31 (12 ) ,970-1

Curran, Emily K; Le, Gem M; Sainani, Kristin L; Propp, Jennifer M; Fisher, Paul Graham (2009. ) Do children and adults differ in survival from medulloblastoma? A study from the SEER registry.Journal of neuro-oncology, , 95 (1 ) ,81-85

Curran, Emily K; Sainani, Kristin L; Le, Gem M; Propp, Jennifer M; Fisher, Paul G (2009. ) Gender affects survival for medulloblastoma only in older children and adults: a study from the Surveillance Epidemiology and End Results Registry.Pediatric blood & cancer, , 52 (1 ) ,60-4

Curran E.;Corrales L.;Kline J. (01-01-2015. ) Targeting the innate immune system as immunotherapy for acute myeloid leukemia.Frontiers in Oncology, , 5 (APR ) ,

Derman B.A.;Streck M.;Wynne J.;Christ T.N.;Curran E.;Stock W.;Knoebel R.W. (02-23-2020. ) Efficacy and toxicity of reduced vs. standard dose pegylated asparaginase in adults with Philadelphi.Leukemia and Lymphoma, , 61 (3 ) ,614-622

Muffly L.;Curran E. (12-06-2019. ) Pediatric-inspired protocols in adult acute lymphoblastic leukemia: Are the results bearing fruit?.Hematology (United States), , 2019 (1 ) ,17-23

Lyu J.;Curran E.;Ji Y. (01-01-2018. ) Bayesian adaptive design for finding the maximum tolerated sequence of doses in multicycle dose-find.JCO Precision Oncology, , 2 ,

Stinchcombe, Thomas E; Zhang, Ying; Vokes, Everett E; Schiller, Joan H; Bradley, Jeffrey D; Kelly, Karen; Curran, Walter J; Schild, Steven E; Movsas, Benjamin; Clamon, Gerald; Govindan, Ramaswamy; Blumenschein, George R; Socinski, Mark A; Ready, Neal E; Akerley, Wallace L; Cohen, Harvey J; Pang, Herbert H; Wang, Xiaofei (2017. ) Pooled Analysis of Individual Patient Data on Concurrent Chemoradiotherapy for Stage III Non-Small-Cell Lung Cancer in Elderly Patients Compared With Younger Patients Who Participated in US National Cancer Institute Cooperative Group Studies.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, , 35 (25 ) ,2885-2892

Salahudeen, Ameen Abdulla; Patel, Manali I; Baas, Paul; Curran, Walter J; Bradley, Jeffrey D; Gandara, David R; Goss, Glenwood D; Mok, Tony S; Ramalingam, Suresh S; Vokes, Everett E; Malik, Shakun M; Wakelee, Heather A (2017. ) Overview of Thoracic Oncology Trials in Cooperative Groups Around the Globe.Clinical lung cancer, , 18 (1 ) ,5-12

Lynch, Thomas J; Bogart, Jeffrey A; Curran, Walter J; DeCamp, Malcolm M; Gandara, David R; Goss, Glenwood; Henschke, Claudia I; Jett, James R; Johnson, Bruce E; Kelly, Karen L; Le Chevalier, Thierry; Mulshine, James L; Scagliotti, Giorgio V; Schiller, Joan H; Shaw, Alice; Thatcher, Nick; Vokes, Everett E; Wood, Douglas E; Hart, Carol (2005. ) Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.Clinical cancer research : an official journal of the American Association for Cancer Research, , 11 (13 Pt 2 ) ,4981s-4983s